Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept conversion versus continued calcineurin inhibitor therapy in adolescent kidney transplant recipients
2022-501677-39-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- May 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of belatacept in Kidney allograft status (RTx) (2 arms), sponsored by Bristol Myers Squibb. Planned start May 2021; status: authorised.
02
Drugs
belatacept
03
Conditions
Kidney allograft status (RTx)
Beyond the preview
Go deeper on 2022-501677-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501677-39-00.